Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of meisoindigo in preparation of medicine for treating acute lung injury

A technology for acute lung injury and methylisoindigo, which can be used in drug combinations, pharmaceutical formulations, organic active ingredients, etc., to solve problems such as reducing mortality and unprincipled treatment of COVID19

Inactive Publication Date: 2021-07-06
NANJING UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the complex pathophysiological features of ALI provide multiple options for its treatment, so far there is no specific drug to treat ALI / ARDS to significantly reduce mortality and improve the quality of life of patients
So far, there are no effective drugs and vaccines for SARS and MERS, so there is no principled treatment for COVID19

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of meisoindigo in preparation of medicine for treating acute lung injury
  • Application of meisoindigo in preparation of medicine for treating acute lung injury
  • Application of meisoindigo in preparation of medicine for treating acute lung injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Pharmacological test of meisoindigo protecting acute lung injury

[0024] 1) Establishment of acute lung injury model in mice

[0025] SPF grade ICR mice, male, 8-10 weeks old, weighing 25±5g. Housed at 22°C, 12 hour light-dark cycle (lights on at 8 am), with free access to food and water. The mice were tested after 7 days of adaptation to the environment. The age and body weight of each group of experimental animals were the same. After the last administration, a single intraperitoneal injection of LPS (10 mg / kg) was used to reproduce the endotoxin-induced ALI model. After 12 hours of modeling, the mice were sacrificed, and lung tissue and blood samples were taken.

[0026] 2) Dosage and method of administration

[0027] The doses of meisoindigo were low dose group: 2.5mg / kg; middle dose group: 5mg / kg; high dose group: 10mg / kg. Three days before modeling, the drug was administered by intragastric administration every day.

[0028] 3) Blood flow measure...

Embodiment 2

[0055] Example 2 Meisoindigo protects the results and analysis of acute lung injury

[0056] 1) Effects of meisoindigo on lung injury and pulmonary blood flow in ALI mice

[0057] like figure 1 As shown in .A, the lungs of the mice in the normal group were smooth, uniformly pink, and soft. Injection of LPS caused hemorrhage, swelling and partial necrosis in mice. Meisoindigo significantly improved lung tissue stasis and damage. Moreover, administration of 10 mg / kg meisoindigo to mice alone did not show toxicity to the lung tissue of mice.

[0058] Decreased blood flow to lung tissue is one of the typical features of lung injury. figure 1 .B shows that the treatment of meisoindigo can significantly improve the decrease of blood flow in lung tissue caused by blood stasis, and the results have significant differences. At the same time, administration of 10 mg / kg meisoindigo to mice alone had no effect on blood flow in lung tissue.

[0059] 2) Effect of meisoindigo on the hi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of meisoindigo in preparation of a medicine for treating acute lung injury and acute respiratory distress syndrome. Experiments prove that meisoindigo can improve the acute lung injury of a mouse and recover the normal physiological structure of the lung tissue of the mouse; the mouse lung tissue blood flow is improved, and the expression level of lung tissue factors is inhibited; the proportion of blood neutrophils is reduced, and the level of serum interleukin 6 is inhibited; and the expression of inflammatory factors is inhibited in an in-vitro cell test. The meisoindigo can be applied to preparation of medicines for acute and chronic lung injury and acute respiratory distress syndrome.

Description

technical field [0001] The patent of the invention relates to the application of meisoindigo in the preparation of medicines for treating acute lung injury and acute respiratory distress syndrome, and belongs to the field of pharmaceutical technology. Background technique [0002] Acute lung injury (ALI) and its more severe form: acute respiratory distress syndrome (ARDS), is direct or indirect lung injury resulting in hypoxemia, dyspnea, or failure due to causes such as shock, severe infection, or trauma It is a clinical syndrome characterized by high morbidity and high mortality. ALI and ARDS are common clinical acute and critical diseases that can develop into multiple organ dysfunction. In this global novel coronavirus infection, it is respiratory failure and acute lung injury that have led to the death of many critically ill patients. [0003] Despite the rapid development of modern medicine, the morbidity and mortality of acute lung injury and acute respiratory distr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/404A61P11/00
CPCA61K31/404A61P11/00
Inventor 徐强吴雪丰史珂王杰李帅飞白梅沈燕吴旭东
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com